Why It Matters

CVS Health faces an existential regulatory threat to its most profitable business segment. Congress is pursuing aggressive, bipartisan PBM reform legislation that could fundamentally restructure how CVS Caremark operates and generates revenue. Bills like the DRUG Act and Patients Before Middlemen Act would "delink" PBM compensation from drug prices, eliminating rebate-based profit models.

Simultaneously, pharmacy closures are accelerating nationwide, with independent operators citing unsustainable PBM reimbursement rates. At least 31 states have enacted nearly 70 drug cost laws in 2025 alone, demonstrating lawmakers won’t wait for federal consensus. Three companies control 80 percent of the market, making the industry a concentrated political target.

By the Numbers

CVS Health spent $2.15 million on federal lobbying in Q3 2025. The healthcare giant has filed 619 disclosures since 2003 with total spending of approximately $180.6 million.

The company’s Q3 team comprises eight lobbyists with significant Capitol Hill pedigree. Katherine Martin Raab brings 8.5 years as a Republican staffer on the House Energy and Commerce Committee. Joy Anna McGlaun served as Deputy Staff Director for the Senate Special Committee on Aging. Tara V. Rountree, hired in April 2025, recently worked as Chief of Staff to Rep. Jennifer McClellan (D-VA).

This represents CVS’s strategy evolution: adding fresh Democratic connections while maintaining Republican relationships through longer-tenured staff like Melissa A. Schulman, lobbying for CVS since 2007.

The Agenda

CVS is lobbying on multiple PBM reform bills, including the PBM Reform Act of 2025, Pharmacy Benefit Manager Transparency Act, DRUG Act, and Patients Before Middlemen Act. These proposals would reshape PBM compensation models, ban spread pricing practices, and increase transparency requirements—directly threatening CVS Caremark’s business structure.

The company also focuses on pharmacy access protections under the Protecting Pharmacies in Medicaid Act and supports the Combatting Organized Retail Crime Act to address theft affecting retail operations.

Broader Context

Multiple reform bills are advancing with bipartisan backing. The House Energy and Commerce Committee and Senate Judiciary Committee have held hearings targeting spread pricing, rebate practices, and market consolidation.

Political pressure stems from pharmacy closures creating "pharmacy deserts" in underserved communities. Members from Senator Katie Britt to Senator Elizabeth Warren have highlighted this crisis. Senator Grassley emphasized that three major PBMs control 80 percent of the market.

Between The Lines

Congressional oversight is intensifying through multiple legislative channels. Key reform advocates like Miller-Meeks and Auchincloss are pushing to delink PBM revenue from drug prices. Senator Cantwell’s office highlighted that transparency legislation would save taxpayers $740 million, while rural-focused lawmakers express mounting concerns about pharmacy closures.

Competitive Landscape

CVS faces intense competition from major rivals including UnitedHealth Group and Elevance Health, which own OptumRx and CarelonRx respectively and are lobbying extensively on the same issues.

Reform advocates are well-organized, with independent pharmacy groups like the American Pharmacy Cooperative actively lobbying for stringent PBM reforms that directly counter large PBM arguments. Political momentum clearly favors reform advocates with broad bipartisan congressional support.

The Bottom Line

CVS confronts unprecedented bipartisan pressure to reform PBMs through multiple bills targeting transparency, pricing practices, and market consolidation. While the company’s experienced lobbying team brings relevant Hill expertise, it faces a crowded advocacy landscape with competitors also lobbying heavily and independent pharmacy groups pushing for stronger reforms that threaten CVS’s core revenue model.

Spot something wrong? Report an issue with this article